Make Informed Investment Decisions with Affordable Access to Experts
Discussing Jazz Pharma's JZP-110 for the treatment of Obstructive Sleep Apnea (OSA) and TONES 3 and TONES 4 study resultsTicker(s): JAZZ, AVDL
Name: Dr Charlene Gamaldo - MD
Institution: Johns Hopkins
- Medical Director, Johns Hopkins Sleep Disorders Center and Associate Professor of Neurology at JHU School of Medicine.
- Actively treats over 1,500 patients with OSA and 30 with narcolepsy.
- Research interests are in the area of sleep medicine, specifically investigating the co-morbid health consequences of chronic sleep deprivation.
Please describe your current practice. How many patients do you treat with OSA?Added By: c_admin
How well tolerated is JZP-110? What % of patient population would not be prescribed the drug due to side effects?Added By: c_admin
On a scale from 1-10, where would you put your level of excitement for JZP-110?Added By: c_admin
Is there anything else on the horizon for OSA that you think is promising?Added By: c_admin
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.